Funding of early stage biotech companies has never been more crucial as scientific breakthroughs and new modalities show huge promise for areas of unmet medical need. As rounds are getting bigger, and early stage capital increasingly comes from diverse geographies and syndicates, how are investors seeing the future of early stage investment? Some of the most active and exciting early-stage investors, backing the next generation of innovators, discuss how the current climate has influenced investment decisions, with money and exits seemingly readily available, and the advice they are giving to portfolio companies and investment prospects about securing the capital they need in the current disrupted world.
Moderator: Samana Brannigan, Innovation Lead and Investor Relations, Innovate UK
Alex Hamilton, Partner, Syncona
Sara Secall, Partner, Inveready
Thibaut Roulon, Investment Director, BpiFrance
John Cassidy, Principal, Arix Bioscience
The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.
Subscribe to our channel for more videos.
Follow us on Twitter: [ Ссылка ]
Visit us at www.lsxleaders.com
